Treatment of breast cancer cell lines ZR‐75‐1 and CAMA‐1 that have low levels of SGK1 (Sommer et al, 2013) with structurally diverse Akt inhibitors (MK‐2206 (Hirai et al, 2010) and AZD5363 (Davies et al, 2012)) for 1 h inhibited phosphorylation of PRAS40 (Thr246, Akt‐specific substrate) as well as NDRG1 (Thr346, Akt and SGK substrate) (Fig 1A). Here, AKT1 is linked to breast cancer.